Washington: An experimental vaccine protects monkeys from not only the two of the deadliest Ebola virus species, but also against a newer Ebola variant BEBOV, identified in 2007.Ebola symptoms are headaches, fevers, chills, muscle aches and loss of appetite. Later, the patients experience diarrhoea, rash, sore throat, vomiting, abdominal pain and chest pain.They have limited kidney and liver functions, besides internal and external bleeding. Patients die of shock, which is eight to 17 days after infection. The Ebola virus also suppresses the immune system.Nancy J Sullivan of the Vaccine Research Centre at the National Institute of Allergy and Infectious Diseases (NIAID) led the study team, including those from the US Army Medical Research Institute of Infectious Diseases and Centres for Disease Control.
"An ideal Ebola vaccine would stimulate broad immunity so that we wouldn`t have to scramble to create entirely new vaccines whenever new virus species are identified," notes Sullivan, according to a NIAID release.Now the research team is evaluating what parts of the T-cell response were critical to the vaccine`s success against BEBOV."Once we identify those critical aspects, we can design future vaccines to better elicit that desired immune cell-based activity and perhaps make a single vaccine that protects against all Ebola virus species," says Sullivan.Their findings appeared on May 20 in the open-access PLoS Pathogens.IANS
Shadows distract autistic kids
Yoga helps fatigue, sleep in cancer survivors